High-quality business currently experiencing weak market structure. Monitor for trend reversal. Valuations remain demanding and supported by current metrics.
SENTINEL REVIEW
Archean Chemical Industries Limited (ACI)•Updated yesterday
🚨 Structural Deterioration Signature: In FY2026, Archean Chemical Industries Limited is experiencing severe operating deterioration, marked by a 35.0% YoY decline in reported net profit to ₹105.4 Cr and a 1596 bps compression in EBIT margins to 5.2%. Profitability is being eroded by persistent negative operating leverage, with interest payments consuming most of the profit, and a 24.2% capex-to-revenue ratio despite revenue contraction. This structural strain is compounded by operational friction: inventory levels rose 67.8% YoY to ₹214.9 Cr, and receivable days increased to 42.5, while cash flow contracted 20.8% YoY to ₹139.6 Cr. Against this liquidity pressure, total debt expanded 161.9% YoY to ₹466.4 Cr, reducing interest coverage to 1.86x and elevating Flagium’s heightened surveillance.
- ✓Risk score improved (QoQ change: -5 pts)
- ✓Profitability margins pressure eased (Margin Compression resolved)
- ✓Relative Growth Weakness resolved this quarter (13 pts)
- ✗Growth expectations are demanding
- ✗Market structure is declining (Stage 4)
- ✗Institutional flow regime is Strong Distribution (-1.78σ)
- ✗Share price is down -5.2% this quarter (from ₹485.85 on 30 Sept to ₹460.8)
- 🔴Investigate Operating Leverage Stress and balance sheet impact
- 🟢Margin Compression resolved in latest filing; verify sustainability in next filing
- 🟢Maintain routine quarterly surveillance; no governance escalation required
- 10.0 ptsGrowth Sustainability
- 21.0 ptsMacro & Sector Calibration
Divergence Radar
Structural Matrix
Risk vs Price TimelineVisualizing the historical relationship between the structural risk score and stock price movement over time.
| Duration | Perf. | Sector Avg | Divergence |
|---|---|---|---|
| 1 Week | +0.91% | -1.46% | +2.37% |
| 1 Month | -4.55% | -6.69% | +2.14% |
| 6 Months | -23.76% | +6.82% | -30.59% |
| 1 Year | -28.52% | +8.93% | -37.45% |
| 2 Year | -28.96% | +47.64% | -76.61% |
| 3 Year | -23.4% | +125.5% | -148.9% |
Business Analysis Methodology
Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.
Financial profile remains stable for now. Pressure is receding in growth sustainability. This suggests the risk profile is currently stabilizing. Risk levels are improving.
Risk Score Composition
Investment Risk Thesis
Current risk score has risen from 5 → 31 over 14 quarters.
- Operating profit margins
Risk Drivers (Active Warnings)
Primary Driver & Insights
Operating leverage stress indicates a high fixed-cost base. This makes operating profit highly sensitive to any marginal drop in sales, compounding downside risk.
Active Risk Objects (8)Free Preview (2 of 8)
Expenses are consistently growing faster than revenues, creating operational pressure.
Margins are in freefall. Operating costs are growing significantly faster than revenue.
Operating margin declined by 16.0 bps YoY for two consecutive quarters.
Operating efficiency is stabilizing. The rate of margin deterioration has slowed.
Unlock All 8 Forensic Signals (6 Additional Warnings Gated)
Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 8 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for Archean Chemical Industries Limited.
Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.
Unlock Interactive Signal Evidence Dossier
Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for Archean Chemical Industries Limited.
Structural Risk Attribution
Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.
Structural History · Last 12 QuartersHistorical Trajectory (12Q)
Risk improved moderately (-5.0 pts), driven by Margin Compression (-22.3 pts) and Relative Growth Weakness (-13.0 pts), partially offset by Operating Leverage Stress (+4.8 pts).
12-Quarter Structural Regimes & Landmark Inflections12Q Structural Regimes & Inflections
Risk deteriorated materially (+21.0 pts), driven by new Relative Growth Weakness (+13.0 pts) and new Operating Leverage Stress (+8.4 pts).
Business Resilience & Benchmark Context
Overall: HEALTHYPEER COMPARISON MATRIX
Ranked surveillance & credit risk comparison against sector peers
Stable
Stable
Stable
Stable
Watch
Watch
* Peer comparison is based on risk signals, not valuation or returns.
Unlock 5-Year Forensic Divergence Cockpit
Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for Archean Chemical Industries Limited.
FINANCIAL STATEMENTS
Working Capital & Forensic Monitor
Operating Cycle Disclosures·6 Fiscal Years
Working Capital Schedule (INR Cr)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|---|
Trade Receivables(₹ Cr) | 127 | 165 | 156 | 118 | — | — |
Inventories(₹ Cr) | 215 | 168 | 127 | 168 | — | — |
Trade Payables(₹ Cr) | 105 | 105 | 100 | 96 | — | — |
Net Working Capital(₹ Cr) | 237 | 228 | 184 | 190 | — | — |
Working Capital / Sales(%) | 21.4% | 21.1% | 13.4% | 12.8% | — | — |
Cash Conversion & Operating Cycle (Days)
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|---|
Cash Conversion Cycle (CCC)(days) | 78d | 77d | 49d | 47d | — | — |
Debtor Days (DSO)(days) | 42d | 56d | 42d | 29d | — | — |
Inventory Days (DIO)(days) | 71d | 57d | 34d | 41d | — | — |
Creditor Days (DPO)(days) | 35d | 36d | 27d | 23d | — | — |
Forensic Accounting Monitor & Divergences
| Metric / Ratio | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|---|
Receivable Growth vs Sales (Δ)(%) | -25.4% | +26.7% | +40.3% | — | — | — |
Inventory Growth vs Sales (Δ)(%) | +25.1% | +53.6% | -16.7% | — | — | — |
Asset Growth vs Sales (Δ)(%) | +8.6% | +37.9% | +24.6% | -16.7% | — | — |
Earnings-to-Cash Divergence (PAT - CFO)(₹ Cr) | -34 | -14 | -60 | -114 | -127 | — |
Accrual Ratio (Accruals / Avg Assets)(%) | -1.4% | -0.6% | -3.2% | -6.9% | -8.3% | — |
Operating Cash Realisation (CFO / EBITDA)(%) | 94.9% | 66.8% | 88.8% | 97.0% | 67.5% | — |
Capitalisation Intensity (CWIP / Assets)(%) | 4.9% | 4.5% | 3.8% | 3.2% | — | — |
Industry Intelligence
Chemicals KPIs| Operating Driver | Quarter | Current Value | Change (QoQ) | Change (YoY) | Industry Median |
|---|---|---|---|---|---|
| Q1 FY2027 | 88.4% | -330 bps ↓ Profitability contraction | -30 bps ↓ Profitability contraction | 48.5% | |
| Q1 FY2027 | 21.9% | +590 bps ↑ Operating efficiency gains | -680 bps ↓ Profitability contraction | 15.5% |
Understanding Chemicals KPIs
Concall & Management Takeaways
No investor earnings call transcripts transcribed for this scrip.
Earnings call intelligence is automatically populated when companies conduct quarterly earnings calls with institutional investors and publish transcripts.
Business quality remains stable.
Current forensic pressure is elevated and improving.
Key risks remain concentrated in growth sustainability and operating leverage.
The risk profile is Early Signals and currently improving. Recent structural triggers in growth sustainability suggest a building pressure on the underlying framework. Material forensic traces are visible in core structural metrics, indicating a progressive erosion of structural stability. Initial structural recovery is visible; monitor for a sustained return to resilience.
Market Expectation Engine
Investor Translation • What the market price is expecting
Expectation EngineAt the current price of ₹461, the market expects this company to grow its revenue by 33.9% every year for the next 5 years. If you think the company will grow faster than 33.9%, current market prices reflect a discount relative to that growth assumption.
Sentinel Takeaway:The market expects future growth significantly above the company's historical delivery. Current market expectations appear demanding relative to the business's track record, resulting in higher expectation risk.
Using the Implied Revenue Model, the market is pricing ACI for 33.9% implied revenue growth versus -9.3% observed 3Y revenue CAGR. Current expectations appear demanding, and trailing fundamentals provide moderate support.
Business Delivery Capacity
Performance quality vs historical benchmarksHistorical business performance currently provides limited support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.
WHY IS EXPECTATION RISK ELEVATED?
Valuation Context
WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?
| Assumption Metric | Required (To justify current price) | Historical Delivery (Average) | Fulfillment Assessment |
|---|---|---|---|
| Revenue Growth (CAGR) | 33.9% | -9.3% | Aggressive |
| Operating Margin (EBIT) | 11.7% | 22.9% | Achievable |
| Free Cash Flow Conversion | -181.9% | -46.6% | Achievable |
*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.
The current valuation assumes business performance well above the company's historical record. Historical operating performance currently provides limited evidence that these expectations are sustainable. Continued revenue acceleration, stronger profitability and stronger cash generation would be required to justify current pricing.
Market Structure Methodology
Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.
The stock remains in a confirmed Stage 4 declining phase. Although institutional participation has improved, trend quality remains weak and momentum continues to deteriorate. Current price action does not yet confirm a structural recovery.
What Is Driving Market Structure?
Market behavior remains consistent with deteriorating financial conditions.
Market Cycle Stage Analysis
Stan Weinstein 4-Stage CycleMomentum & Institutional Flow
Methodology & Regulatory Disclaimer
Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.
Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.
📬 Flagium Risk Brief — Track forensic risks on ACI & 3 market anomalies weekly
See a sample issue →